Biocompatibility and new fluids

Peritoneal Dialysis International

Volumn 19, Issue SUPPL. 2, 1999, Pages

  Coles, Gerald A ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Cardiff Royal Infirmary   (United Kingdom)

Author keywords

Biocompatibility; Clinical significance; Glucose; Glucose degradation products; Improved dialysate; New peritoneal dialysis fluids

Indexed keywords

AMINO ACID; BICARBONATE; CHONDROITIN SULFATE; DERMATAN SULFATE; GLUCOSE; GLUCOSE POLYMER; GLYCOSAMINOGLYCAN; HYALURONIC ACID; LACTIC ACID; LOW MOLECULAR WEIGHT HEPARIN; N ACETYLGLUCOSAMINE; PERITONEAL DIALYSIS FLUID; PHOSPHATIDYLCHOLINE; PLASTICIZER; PYRUVIC ACID;

BIOCOMPATIBILITY; CLINICAL TRIAL; CONFERENCE PAPER; DIALYSATE; EXPERIMENTAL MODEL; HUMAN; LABORATORY TEST; NONHUMAN; PH; PRIORITY JOURNAL; TOXICITY TESTING;

EID: 0033381466     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901902s44     Document Type: Conference Paper

References (34)

1. Topley N, Coles GA, Williams JD. Biocompatibility studies on peritoneal cells. Perit Dial Int. 1994; 14(Supp 3): S21-8.
2. Breborowicz A, Balaskas E, Oreopoulos GD, Martis L, Serkes K, Oreopoulos DG. In vitro study of the effect of osmotic solutes on the interactions between cells from the peritoneum and peritoneal cavity. Perit Dial Int. 1994; 14:149-54.
3. Breborowicz A, Rodela H, Karon J, Martis L, Oreopoulos DG. In vitro simulation of the effect of peritoneal dialysis solution on mesothelial cells. Am J Kidney Dis. 1997; 29:404-9.
4. de Fijter CWH, Verbrugh HA, Peters EDJ, Oe PL, van der Meulen J, Verhoef J, et al. In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD. Clin Nephrol. 1993; 39:75-80.
5. Wang T, Chen C, Heimbürger O, Waniewski J, Bergström J, Lindholm B. Hyaluronan decreases peritoneal fluid absorption in peritoneal dialysis. J Am Soc Nephrol. 1997; 8:1915-20.
6. Gallimore B, Gagnon R, Richards GK. Response of chronic renal failure mice to peritoneal Staphylococcus epidermidis challenge: Impact of repeated peritoneal installation of dialysis solution. Am J Kidney Dis. 1989; 14:184-95.
7. Wu G, Wieczorowska-Tobis K, Polubinska A, Korybalska K, Filas V, Tam P, et al. N-acetylglucosamine changes permeability of peritoneum during chronic peritoneal dialysis in rats. Perit Dial Int. 1998; 18: 217-24.
8. Gotloib L, Wajsbrot V, Shostak A, Kushnier R. Acute and long-term change observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions. Nephron. 1995; 70:466-77.
9. Di Paolo N, Garosi G, Petrini G, Monaci G. Morphological and morphometric changes in mesothelial cells during peritoneal dialysis in the rabbit. Nephron. 1996; 74:594-9.
10. Wieslander AP, Nordin MK, Martinson E, Kjellstrand PTT, Boberg UC. Heat sterilised PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes. Clin Nephrol. 1993; 39:343-8.
11. Liberek T, Topley N, Jörres A, Petersen MM, Coles GA, Gahl GM, et al. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron. 1993; 65:260-5.
12. Douvdevani A, Rapoport J, Konforty A, Yulzari R, Moran A, Chaimovitz C. Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages. J Am Soc Nephrol. 1995; 6:207-13.
13. Guo W, Willen R, Andersson R, Parsson H, Liu X, Johansson K, et al. Morphological response of the peritoneum and spleen to intraperitoneal materials. Int J Artif Organs. 1993; 16:276-84.
14. Fracasso A, Coli U, Landini S, et al. Peritoneal sclerosis. Role of plasticizers. ASAIO Trans. 1987; 33:676-82.
15. Tsai T-J, Yen C-J, Fang C-C, Yang C-C, Lee P-H, Yen T-S. Effect of intraperitoneally administered agents on human peritoneal mesothelial cell growth. Nephron. 1995; 71:23-8.
16. Mackenzie R, Williams JD, Mosely A, Argyle R, Coles GA, Holmes CJ, et al. In vivo exposure to bicarbonate/ lactate (TBL) and bicarbonate (TB) buffered peritoneal dialysis fluids (PDF) improves peritoneal macrophage (PMΦ) function [Abstract]. J Am Soc Nephrol. 1996; 7:1431.
17. Davies SJ, Bryan J, Philipps L, Russell GI. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant. 1996; 11:498-506.
18. De Alvaro F, Castro MJ, Dapena F, Bajo MA, Fernandez-Reyes MJ, Romero JR, et al. Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in Peritoneal Dialysis. Toronto: Peritoneal Dialysis Publications, 1993; 9:56-61.
19. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int. 1997; 51:182-6.
20. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med. 1989; 170:1387-407.
21. Fujimori A, Naito H, Miyazaki T, Azuma M, Hashimoto S, Horikawa S, et al. Elevation of interleukin 6 in the dialysate reflects peritoneal stimuli and deterioration of peritoneal function. Nephron. 1996; 74:471-2.
22. Honda K, Nitta K, Horita H, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron. 1996; 72:171-6.
23. Monquil MCJ, Imholz ALT, Struijk DG, Krediet RT. Does impaired transcellular water transport contribute to net ultrafiltration failure during CAPD? Perit Dial Int. 1995; 15:42-8.
24. Ho-dac-Pannekeet MM, Struijk DG, Krediet RT. Improvement of transcellular water transport by treatment with glucose free dialysate in patients with ultrafiltration failure [Abstract]. Nephrol Dial Transplant. 1996; 11:A255.
25. Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Nask R, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int. 1998; 53:1061-7.
26. Coles GA, Gokal R, Ogg C, Jani F, O'Donoghue D, Cancarini GC, et al. A randomized controlled trial of a bicarbonate- and a bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int. 1997; 17:48-51.
27. Schambye HT, Pedersen FB, Wang P. Bicarbonate is not the ultimate answer to the biocompatibility problems of CAPD solutions: A cytotoxicity test of CAPD solutions and effluents. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in Peritoneal Dialysis. Toronto: Peritoneal Dialysis Bulletin, 1992; 8:41-6.
28. Mahiout A, Brunkhorst R. Pyruvate anions neutralize peritoneal dialysate cytotoxicity. Nephrol Dial Transplant. 1995; 10:391-4.
29. Mistry CD, Gokal R, Peers E, and the Midas Study Group. A randomised multicentre clinical trial comparing isoosmolar icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int. 1994; 46:496-503.
30. Wieslander AP, Deppisch R, Svensson E, Forsback G, Speidel R, Rippe B. In vitro biocompatibility of a heat-sterilized, low-toxic and less acidic fluid for peritoneal dialysis. Perit Dial Int. 1995; 15:158-64.
31. Cooker LA, Luneburg P, Faict D, Choo C, Holmes CJ. Reduced glucose degradation products in bicarbonate/ lactate-buffered peritoneal dialysis solutions produced in two-chambered bags. Perit Dial Int. 1997; 17:373-8.
32. Breborowicz A, Wieczorowska K, Witowski J, Martis L, Oreopoulos DG. Phosphatidylcholine and chondroitin sulfate in peritoneal dialysis fluids to preserve membrane function. Perit Dial Int. 1994; 14(Suppl 3): S139-44.
33. Breborowicz A, Wieczorowska K, Martis L, Oreopoulos DG. Glycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats. Nephron. 1994; 67:346-50.
34. Bazzato G, Fracasso A, Gambaro G, Baggio B. Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis. Lancet. 1995; 346:740-1.